Table 2.
Rates of cirrhosis, hepatitis B virus and hepatitis C virus infection in studies with more than 10 cases of combined hepatocellular-cholangiocarcinoma
| Author | Country | Year | No. of | Male/Female | Age | Cirrhosis | HBsAg | HCV-Ab |
| patients | year1 | n (%) | n (%) | n (%) | ||||
| Aoki et al[4] | Japan | 1993 | 20 | 18/2 | 55.8 | 12 (60) | 5 (25) | NA |
| Haratake et al[5] | Japan | 1995 | 13 | 10/3 | 64.8 | 11 (84.6) | 1 (7.6) | 3/5 (60) |
| Maeda et al[6] | Japan | 1995 | 29 | 27/2 | 59.8 | 10 (34.5) | 6 (22.2) | 10/16 (62.5) |
| Taguchi et al[7] | Japan | 1996 | 23 | 15/8 | 64.0 | 9 (39) | 4 (17) | 14/20 (70) |
| Sasaki et al[8] | Japan | 1999 | 21 | NA | NA | 17 (80.9) | 7 (33.3) | 5/16 (31.3) |
| Yano et al[9] | Japan | 2003 | 26 | 23/3 | 57.0 | 14 (54) | 7 (27) | 10 (38) |
| Sanada et al[10] | Japan | 2005 | 11 | 7/4 | 66.4 | 5 (46) | 5 (46) | 6 (55) |
| Aishima et al[11] | Japan | 2006 | 40 | 36/4 | 58.1 | 11 (27.5) | 17/37 (45.9) | 12/32 (37.5) |
| Wakasa et al[12] | Japan | 2007 | 18 | 14/4 | 56.7 | 5 (27.7) | 4 (22.2) | 7/16 (43.8) |
| Ariizumi et al[13] | Japan | 2011 | 44 | 31/11 | 65.0 | 23 (52) | 11 (25) | 24 (55) |
| Akiba et al[14] | Japan | 2013 | 54 | 45/9 | 66.0 | 14 (25.9) | 14 (25.9) | 21 (38.8) |
| Koh et al[16] | Korea | 2005 | 24 | 16/8 | 55.0 | 13 (54.2) | 13 (54.2) | 3 (12.5) |
| Lee et al[17] | Korea | 2006 | 33 | 22/11 | 52.0 | 16 (48.5) | 16 (48.5) | 4 (12.1) |
| Shin et al[18] | Korea | 2007 | 12 | 11/1 | 48.1 | 8 (66.6) | 9 (75) | 1 (8.3) |
| Kim et al[19] | Korea | 2009 | 29 | 23/6 | 53.0 | 17 (58.6) | 22 (75.9) | 1 (3.4) |
| Kim et al[20] | Korea | 2010 | 50 | 41/9 | 56.3 | 27 (54) | 40 (80) | 2 (4) |
| Lee et al[21] | Korea | 2011 | 30 | 26/4 | 61.1 | 22 (73.3) | 19 (63.3) | 1 (3.3) |
| Park et al[22] | Korea | 2011 | 21 | 15/6 | 59.0 | 13 (62) | 17 (81) | 0 |
| Zuo et al[23] | China | 2007 | 15 | 11/4 | 49.0 | 11 (73.3) | 11 (73.3) | 3 (20) |
| Zhang et al[24] | China | 2008 | 12 | 8/4 | 48.0 | 7 (58.3) | 7 (58.3) | 0 |
| Yu et al[25] | China | 2011 | 14 | 12/2 | 53.6 | 10 (71.4) | 13 (92.8) | 0 |
| Yin et al[26] | China | 2012 | 103 | 83/20 | 50.0 | 69 (66.9) | 76 (73.4) | 1 (0.97) |
| Zhan et al[27] | China | 2012 | 27 | 24/3 | 58.3 | 10 (37) | 8 (29.6) | 4 (14.8) |
| Yap et al[28] | Taiwan | 2012 | 11 | 8/3 | 61.0 | 8 (72) | 6 (54) | 2 (18) |
| Lee et al[29] | Taiwan | 2013 | 65 | 48/17 | 55.7 | 27/47 (57.4) | 32 (49.2) | 11 (16.9) |
| Ng et al[30] | Hong Kong | 1998 | 21 | 18/3 | 49.7 | 10 (47.6) | 12/16 (75) | NA |
| Chantajitr et al[31] | Thailand | 2006 | 25 | 18/7 | 53.4 | 11 (50.0) | 12 (66.7) | 2 (13.3) |
| Phongkitkarun et al[32] | Thailand | 2007 | 10 | 7/3 | 53.5 | 5 (50) | 4 (40) | 1 (10) |
| Jarnagin et al[33] | USA | 2002 | 27 | 14/13 | 61.0 | 0 | 4 (15)2 | NA |
| Panjala et al[34] | USA | 2010 | 12 | 8/4 | 61.0 | 10 (83.3) | 2 (16.6) | 5 (41.6) |
| Cazals-hatem et al[35] | France | 2004 | 15 | 14/1 | 59.8 | 4 (27) | NA | 4 (27) |
| Portolani et al[36] | Italy | 2008 | 18 | NA | NA | 14 (77.7) | 3 (16.6) | 11 (61.1) |
1
Mean or median;
2
Hepatitis B or C. NA: Not available; HBsAg: Hepatitis B surface antigen; HCV: Hepatitis C virus; HCV-Ab: Anti-HCV antibody.